Literature DB >> 27177605

Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.

Jonas Schreiber1, John McNally2, Krishna Chodavarapu2, Evguenia Svarovskaia2, Christophe Moreno1.   

Abstract

During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983-985).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27177605     DOI： 10.1002/hep.28636

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


  9 in total

Review 1.  Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.

Authors:  Fazia Mir; Alp S Kahveci; Jamal A Ibdah; Veysel Tahan
Journal:  Drug Des Devel Ther       Date:  2017-02-23       Impact factor: 4.162

2.  A potent human neutralizing antibody Fc-dependently reduces established HBV infections.

Authors:  Dan Li; Wenhui He; Ximing Liu; Sanduo Zheng; Yonghe Qi; Huiyu Li; Fengfeng Mao; Juan Liu; Yinyan Sun; Lijing Pan; Kaixin Du; Keqiong Ye; Wenhui Li; Jianhua Sui
Journal:  Elife       Date:  2017-09-26       Impact factor: 8.140

3.  Distribution of HCV genotypes in Belgium from 2008 to 2015.

Authors:  Lobna Bouacida; Vanessa Suin; Veronik Hutse; Michaël Boudewijns; Reinoud Cartuyvels; Laurent Debaisieux; Emmanuel De Laere; Marie Hallin; Nicolas Hougardy; Katrien Lagrou; Els Oris; Elizaveta Padalko; Marijke Reynders; Gatien Roussel; Jean-Marc Senterre; Michel Stalpaert; Dominique Ursi; Carl Vael; Dolores Vaira; Jos Van Acker; Walter Verstrepen; Steven Van Gucht; Benoit Kabamba; Sophie Quoilin; Gaëtan Muyldermans
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

4.  Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.

Authors:  Charlotte Hedskog; Bandita Parhy; Silvia Chang; Stefan Zeuzem; Christophe Moreno; Stephen D Shafran; Sergio M Borgia; Tarik Asselah; Laurent Alric; Armand Abergel; Jyh-Jou Chen; Jane Collier; Dharmesh Kapoor; Robert H Hyland; Peter Simmonds; Hongmei Mo; Evguenia S Svarovskaia
Journal:  Open Forum Infect Dis       Date:  2019-02-22       Impact factor: 3.835

Review 5.  Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update.

Authors:  Elise J Smolders; Anouk M E Jansen; Peter G J Ter Horst; Jürgen Rockstroh; David J Back; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 6.  Current therapy for chronic hepatitis C: The role of direct-acting antivirals.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Antiviral Res       Date:  2017-02-24       Impact factor: 5.970

7.  Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection.

Authors:  Bryan Sackey; Jana G Shults; Troy A Moore; Rachel Rogers; Mina Mehvar; Joshua G King
Journal:  Ment Health Clin       Date:  2018-04-26

8.  Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.

Authors:  Chris Davis; George S Mgomella; Ana da Silva Filipe; Eric H Frost; Genevieve Giroux; Joseph Hughes; Catherine Hogan; Pontiano Kaleebu; Gershim Asiki; John McLauchlan; Marc Niebel; Ponsiano Ocama; Cristina Pomila; Oliver G Pybus; Jacques Pépin; Peter Simmonds; Joshua B Singer; Vattipally B Sreenu; Clara Wekesa; Elizabeth H Young; Donald G Murphy; Manj Sandhu; Emma C Thomson
Journal:  Hepatology       Date:  2019-03-22       Impact factor: 17.425

Review 9.  Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.

Authors:  Rajiv Shah; Lucrece Ahovegbe; Marc Niebel; James Shepherd; Emma C Thomson
Journal:  J Hepatol       Date:  2021-05-08       Impact factor: 25.083
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.